Regulatory Sourcebook eBook
Read the article:
Considering Titanium Dioxide Regulatory Changes
Read the eBook:
Pharmaceutical Technology’s Regulatory Sourcebook eBook.
Considering Titanium Dioxide Regulatory Changes
News
Article
Pharmaceutical TechnologyPharmaceutical Technology, Regulatory Sourcebook, September 2021
Volume 2021 eBook
Issue 3
EFSA’s evaluation of risk in food products raises implications for drug product formulations.
Kateryna Kon/Adobe.Stock.com
Titanium dioxide is widely used for adding opacity and brightness in many products. A May 2021 evaluation from the European Food Safety Authority (EFSA), which declared that titanium dioxide is unsafe for food products, alarmed other industries that rely on the ingredient. Although changes are not required in pharmaceutical products, some supplement and drug manufacturers and their suppliers have considered potential alternatives.
Read this article in Pharmaceutical Technology’s Regulatory Sourcebook eBook.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 8-9
Citation
When referring to this article, please cite it as J. Markarian, “Considering Titanium Dioxide Regulatory Changes,” Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).
Articles in this issue
Understanding Combination Product Regulations
Considering Titanium Dioxide Regulatory Changes
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
Changing the Course of Drug Shortages
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices
Industry Organizations Assist Pharma During the Pandemic and Beyond
Mapping Out Pharma’s Regulatory Future in Europe
Recent Videos
Related Content
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Article
Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
